With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.103946-54-9,4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid,as a common compound, the synthetic route is as follows.
As shown in Figure 1, 4′-methyl-[2,2’dipyridyl]-4-carboxylic acid (0.3 g, 1.4 mmol) (purchased from Zhengzhou Alpha) and N-hydroxysuccinimide (NHS, 0.257 g, 2.24 mmol) were used and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 0.322 g, 1.68 mmol) was dispersed in a 15 mL DMF (N,N-dimethylformamide) port flask , Heat to 50 C, reaction for 12h. After the reaction was completed, the DMF solution was decontaminated under reduced pressure. Deionized water (50 mL) was added and solids precipitated.Dichloromethane extraction (15 mL, extraction 3 times) takes a light yellow organic layer. Then dry with anhydrous sodium sulfate.Take the filtrate, take the filtrate, and evaporate the filtrate with a rotary evaporator.A pale white solid is obtained, which is the active ester of dipyridylcarboxyl: 2,5-dicarbonyl-1-pyrrolidinyl 4′-methyl-[2,2′-bipyridine]-4-carboxylate (product 1), yield 65.2%., 103946-54-9
103946-54-9 4′-Methyl-[2,2′-bipyridine]-4-carboxylic acid 11127621, acatalyst-ligand compound, is more and more widely used in various fields.
Reference£º
Patent; Jinan University; Guangzhou Medicine Jianyansuo; Chen Tianfeng; Tian Yiqiao; Du Biying; Huang Yanyu; Gao Pan; (22 pag.)CN107573384; (2018); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI